Tirzepatide can strip off more than 22 kg in 40 weeks. A new randomized trial shows that, without lifting, about 4.7 kg of that loss was lean soft tissue, and strength went backward. Lifting three times a week changed that picture.
The trial, published in Nature Medicine (online ahead of print, 2026), is one of the clearest human tests yet of whether resistance exercise protects the body's lean tissue during incretin-based weight loss.
The Setup: 120 People, 40 Weeks, One Drug
Researchers at the University of Western Australia and collaborating institutions enrolled 120 adults with overweight or obesity. Everyone received tirzepatide. Participants were then randomized to one of two arms:
- Tirzepatide alone (T): usual activities
- Tirzepatide + resistance exercise (T+REx): thrice-weekly resistance exercise training
The intervention ran 40 weeks. Tirzepatide was reported as safe, and most participants tolerated up-titration to 15 mg weekly, the top dose. Adherence to the resistance exercise program was 91%.
This was a human randomized controlled trial, not an animal or cell study. The trial is registered (ACTRN12623001236684).
The Headline Numbers
Weight and fat loss: the same in both groups
Lifting did not slow the drug's main effect.
- Weight loss: T = -22.61 kg vs T+REx = -22.28 kg (P = 0.694)
- Total fat mass loss: T = -17.19 kg vs T+REx = -17.98 kg (P = 0.700)
The between-group fat difference was -0.77 kg (95% CI -2.14 to 0.60 kg), so there was no meaningful gap.
Lean mass: where lifting made a difference
- Total lean soft tissue mass: T = -4.67 kg vs T+REx = -3.57 kg (P < 0.001)
- Between-group difference: 1.09 kg (95% CI 0.43 to 1.75 kg)
- Appendicular lean soft tissue mass (arms and legs): T = -3.55 kg vs T+REx = -2.92 kg (P < 0.001)
The lifters did not gain lean mass. They lost less of it. By my own arithmetic from the reported figures, that is roughly a quarter less lean loss than the drug-only group. The paper's abstract describes the effect as attenuation, and that is the accurate word.
Strength: down on the drug alone, up with lifting
The strength results were the starkest.
| Test | Tirzepatide alone | Tirzepatide + REx |
|---|---|---|
| Bench press | -4.09 kg | +4.68 kg |
| Lat pulldown | -4.42 kg | +8.58 kg |
| Knee extension | -4.42 kg | +5.88 kg |
All differences versus tirzepatide alone were significant (P < 0.001). Without training, upper and lower body strength fell. With training, it rose on every test.
The Training Protocol: What the Abstract Tells Us
The abstract confirms only a few details:
- Frequency: three times per week
- Duration: 40 weeks
- Adherence: 91%
- Muscle groups assessed: bench press (upper body push), lat pulldown (upper body pull) and knee extension (lower body)
It does not report sets, repetitions, loads or progression. Those details should be in the full paper, so check it before copying a specific program. The tested exercises suggest a sensible template: a push, a pull and a leg movement.
Practical Takeaways
1. Plan on three sessions a week. That is the schedule that produced the results, and participants stuck to it 91% of the time.
2. Cover the whole body. The strength gains showed up in pushing, pulling and leg exercises, so a full-body plan is a reasonable approach.
3. Expect to protect muscle, not necessarily build it. Both groups lost lean mass. Lifting reduced the loss by about 1.1 kg.
4. Don't expect lifting to cost you fat loss. Weight and fat loss were statistically similar between groups.
5. Protein. The abstract says nothing about protein intake, so this trial can't give a protein target. General sports-nutrition and sarcopenia guidance emphasizes adequate protein alongside resistance training. Discuss specific amounts with a clinician or dietitian.
6. Dose. Most participants reached 15 mg weekly, but the dose is set by a prescriber, not by this trial. Lifting is an add-on, not a reason to change your dose.
Who It's For
The findings are most relevant to adults with overweight or obesity taking tirzepatide (Mounjaro/Zepbound). The concern about losing muscle is especially important for older adults, who have less lean tissue to spare and are more vulnerable to weakness and falls. The abstract does not report the participants' ages or run a subgroup analysis for older people, so it does not show that the results hold for them. Older adults and anyone with joint, heart or other medical conditions should check with a clinician and ideally get coaching before starting a lifting program.
Caveats Worth Knowing
- "Lean soft tissue" is not pure muscle. It includes water and organ tissue. Strength gains support a functional benefit, but the measure is not a direct muscle count.
- Some lean mass was still lost. Lifters lost 3.57 kg of lean soft tissue, so resistance exercise attenuates the loss without eliminating it.
- Duration. The data cover 40 weeks. What happens after stopping the drug or the training is not addressed in the abstract.
- Disclosures. Several authors reported speaker honoraria or advisory roles with pharmaceutical companies, including Eli Lilly, which makes tirzepatide. All honoraria were paid to the University of Western Australia. One author is a shareholder and clinical advisor to ProGenis Pharmaceuticals.
The Bottom Line
Tirzepatide delivers large weight and fat loss on its own, but it also took lean mass and strength with it. Adding lifting three times a week for 40 weeks kept the fat loss the same, cut lean mass loss by about 1.1 kg and reversed the strength decline. For people on a GLP-1-class drug, this trial argues for making resistance training part of the treatment plan. This article is for information only and is not medical advice.